开云app官网登录入口网页版-官方正版

#T细胞免疫疗法#

14篇内容 | 944人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1943641, encodeId=47bc1943641b3, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=Cancer Cell：效果更强劲！廖学斌/魏来合作揭示HPK1可成为T细胞免疫疗法的靶点, objectType=article, longId=200189, objectId=f76d20018958, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f76d20018958, replyNumber=0, likeNumber=94, createdTime=2020-11-14, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f76d20018958, moduleTitle=Cancer Cell：效果更强劲！廖学斌/魏来合作揭示HPK1可成为T细胞免疫疗法的靶点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f76d20018958)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943644, encodeId=98741943644c7, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=北京发布《CAR-T细胞免疫疗法临床研究伦理审查指南》, objectType=article, longId=205468, objectId=b398205468c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b398205468c7, replyNumber=0, likeNumber=99, createdTime=2021-08-15, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b398205468c7, moduleTitle=北京发布《CAR-T细胞免疫疗法临床研究伦理审查指南》, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b398205468c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943642, encodeId=2a6f194364231, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果, objectType=article, longId=200586, objectId=adbc20058698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adbc20058698, replyNumber=0, likeNumber=84, createdTime=2021-04-09, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adbc20058698, moduleTitle=EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=adbc20058698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943643, encodeId=8910194364381, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=CAR-T细胞免疫疗法临床研究与伦理审查实践, objectType=article, longId=202609, objectId=56f8202609e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f8202609e1, replyNumber=0, likeNumber=0, createdTime=2021-05-02, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f8202609e1, moduleTitle=CAR-T细胞免疫疗法临床研究与伦理审查实践, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=56f8202609e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943638, encodeId=fa5c194363858, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物, objectType=article, longId=192035, objectId=9c5119203548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c5119203548, replyNumber=0, likeNumber=58, createdTime=2020-12-31, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c5119203548, moduleTitle=59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9c5119203548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943640, encodeId=ebf9194364030, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=Blood重磅｜CAR-NK再度出世，竟比CAR-T细胞免疫疗法更有效？, objectType=article, longId=198778, objectId=f56d198e7883, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f56d198e7883, replyNumber=0, likeNumber=65, createdTime=2020-11-02, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f56d198e7883, moduleTitle=Blood重磅｜CAR-NK再度出世，竟比CAR-T细胞免疫疗法更有效？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f56d198e7883)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943637, encodeId=9bbc194363e6e, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, objectType=article, longId=191240, objectId=fac619124043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fac619124043, replyNumber=0, likeNumber=87, createdTime=2020-05-31, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fac619124043, moduleTitle=CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fac619124043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943639, encodeId=d34f194363914, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=重大突破！《自然》杂志：T细胞免疫疗法完全治愈晚期癌症, objectType=article, longId=194508, objectId=fb54194508d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb54194508d4, replyNumber=0, likeNumber=67, createdTime=2021-02-04, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb54194508d4, moduleTitle=重大突破！《自然》杂志：T细胞免疫疗法完全治愈晚期癌症, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fb54194508d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943636, encodeId=531c194363617, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, objectType=article, longId=173300, objectId=ce3d1e330034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3d1e330034, replyNumber=0, likeNumber=87, createdTime=2019-11-10, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3d1e330034, moduleTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ce3d1e330034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943634, encodeId=465a194363483, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=Blood：靶向CD19的嵌合抗原受体修饰的T细胞免疫疗法的感染性并发症研究。, objectType=article, longId=116944, objectId=9e6111694445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e6111694445, replyNumber=0, likeNumber=84, createdTime=2017-11-01, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e6111694445, moduleTitle=Blood：靶向CD19的嵌合抗原受体修饰的T细胞免疫疗法的感染性并发症研究。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9e6111694445)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943635, encodeId=e5e919436358a, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=Blood：用于管理具有复发风险的造血干细胞移植后患者的T细胞免疫疗法的进展。, objectType=article, longId=117241, objectId=458d11e2415b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=458d11e2415b, replyNumber=0, likeNumber=70, createdTime=2018-01-18, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=458d11e2415b, moduleTitle=Blood：用于管理具有复发风险的造血干细胞移植后患者的T细胞免疫疗法的进展。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=458d11e2415b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943633, encodeId=10a51943633a6, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=T细胞免疫疗法“热度”不减，巨噬细胞免疫疗法也在“发力”！, objectType=article, longId=95128, objectId=155295128ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=155295128ed, replyNumber=0, likeNumber=68, createdTime=2017-11-05, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=155295128ed, moduleTitle=T细胞免疫疗法“热度”不减，巨噬细胞免疫疗法也在“发力”！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=155295128ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943631, encodeId=6ab11943631f2, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=Science：CAR-T细胞免疫疗法重要突破, objectType=article, longId=81293, objectId=8c95812931c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c95812931c, replyNumber=0, likeNumber=80, createdTime=2017-05-02, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c95812931c, moduleTitle=Science：CAR-T细胞免疫疗法重要突破, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8c95812931c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943632, encodeId=e7d11943632b9, content=<a href='/topic/show?id=42b918013fe' target=_blank style='color:#2F92EE;'>#T细胞免疫疗法#</a>, objectTitle=Cell重磅癌症专刊！Carl June全新深度好文：让T细胞免疫疗法更“牛”, objectType=article, longId=88713, objectId=4e1088e1325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1088e1325, replyNumber=0, likeNumber=85, createdTime=2017-09-11, rootId=0, userName=天堂的云, userId=68f2317, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1088e1325, moduleTitle=Cell重磅癌症专刊！Carl June全新深度好文：让T细胞免疫疗法更“牛”, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4e1088e1325)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

T细胞免疫疗法

2020-05-29

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

Cancer Cell：效果更强劲！廖学斌/魏来合作揭示HPK1可成为T细胞免疫疗法的靶点

2020-11-14

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

北京发布《CAR-T细胞免疫疗法临床研究伦理审查指南》

2021-08-15

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果

2021-04-09

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

CAR-T细胞免疫疗法临床研究与伦理审查实践

2021-05-02

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

59岁患者接受CAR-T细胞免疫疗法后超过3年无癌症标志物

2020-12-31

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

Blood重磅｜CAR-NK再度出世，竟比CAR-T细胞免疫疗法更有效？

2020-11-02

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

CAR-T细胞免疫疗法（idecabtagene vicleucel）治疗多发性骨髓瘤

2020-05-31

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

重大突破！《自然》杂志：T细胞免疫疗法完全治愈晚期癌症

2021-02-04

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解

2019-11-10

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

Blood：靶向CD19的嵌合抗原受体修饰的T细胞免疫疗法的感染性并发症研究。

2017-11-01

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

Blood：用于管理具有复发风险的造血干细胞移植后患者的T细胞免疫疗法的进展。

2018-01-18

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

T细胞免疫疗法“热度”不减，巨噬细胞免疫疗法也在“发力”！

2017-11-05

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

Science：CAR-T细胞免疫疗法重要突破

2017-05-02

天堂的云 (审核中...)

前往app查看评论内容

#T细胞免疫疗法#

Cell重磅癌症专刊！Carl June全新深度好文：让T细胞免疫疗法更“牛”

2017-09-11

科室
- - 订阅+
  - 更多科室
工具
服务